Eli lilly stock forecast 2030 is reinforced by strategic

Eli Lilly stock forecast 2030 is reinforced by strategic partnerships and acquisitions that broaden therapeutic scope, enabling top-line growth beyond current core competencies. Along with its strong performance last year, Lilly has also been a great stock to own for the long term. With so many exciting opportunities ahead, I think now is a great time to begin building a position in the stock. However, Eli Lilly trades at a rich valuation compared to its peers, which can lead to a correction if revenue growth slows down. Eli Lilly stock forecast 2030 benefits from currency-hedged global expansion, particularly in emerging markets where healthcare infrastructure investment is accelerating demand for branded treatments.